Summary
Edwards Lifesciences Corporation (EW) reported its third-quarter 2012 results, showcasing strong revenue growth, particularly driven by its Transcatheter Heart Valves segment, which saw a significant increase primarily due to the U.S. launch of the Edwards SAPIEN valve. The company demonstrated improved gross profit margins, benefiting from a favorable product mix and foreign currency exchange rate impacts. Despite a slight decrease in Surgical Heart Valve Therapy sales, overall net sales increased by 8.5% year-over-year for the quarter. The company also continues to invest in research and development, particularly in its Transcatheter Heart Valve program, which is a key growth driver. Investors should note the ongoing legal proceedings with Medtronic, though management believes these will not have a material adverse effect on the company's financial position. The company also completed the acquisition of BMEYE, B.V. post-period, expanding its capabilities in hemodynamic monitoring. Financially, the company reported solid earnings per share and maintained a healthy cash flow from operations. The balance sheet shows an increase in cash and cash equivalents and a manageable debt level. The company also continued its share repurchase program, demonstrating a commitment to returning value to shareholders. Overall, the results indicate a company experiencing significant growth, especially in its innovative transcatheter valve offerings, while managing various operational and legal complexities.
Financial Highlights
43 data points| Revenue | $447.90M |
| Cost of Revenue | $111.70M |
| Gross Profit | $336.20M |
| R&D Expenses | $73.80M |
| SG&A Expenses | $167.80M |
| Net Income | $69.20M |
| EPS (Basic) | $0.10 |
| EPS (Diluted) | $0.10 |
| Shares Outstanding (Basic) | 694.20M |
| Shares Outstanding (Diluted) | 714.00M |
Key Highlights
- 1Net sales increased by 8.5% to $447.9 million for the third quarter of 2012 compared to the same period in 2011.
- 2Transcatheter Heart Valves segment sales surged by 49.9% to $123.8 million, largely driven by the U.S. launch of the Edwards SAPIEN valve.
- 3Gross profit margin improved to 75.1% from 69.6% in the prior year's quarter, benefiting from a favorable product mix and currency effects.
- 4Diluted earnings per share rose to $0.58 from $0.43 in the prior year's quarter.
- 5The company repurchased approximately 0.7 million shares under accelerated share repurchase agreements and ongoing stock repurchase programs, demonstrating capital return to shareholders.
- 6The company recorded $7.0 million in special charges related to intellectual property licensing during the nine months ended September 30, 2012.
- 7Post-period, Edwards Lifesciences acquired BMEYE, B.V. for approximately $42 million, strengthening its hemodynamic monitoring capabilities.